Actinium Pharmaceuticals
ATNM
28 hedge funds and large institutions have $6.39M invested in Actinium Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 1 reducing their positions, and 6 closing their positions.
1,000% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 1
5.7% less ownership
Funds ownership: 17.74% → 12.04% (-5.7%)
10% less funds holding
Funds holding: 31 → 28 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
81% less capital inflows, than outflows
Capital inflows: $594K | Capital outflows: $3.13M
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$230K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$109K |
| 3 |
D.A. Davidson & Co
Great Falls,
Montana
|
+$73.1K |
| 4 |
Armistice Capital
New York
|
+$55K |
| 5 |
Credit Suisse
Zurich,
Switzerland
|
+$40.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.4M |
| 2 |
Sio Capital Management
New York
|
-$915K |
| 3 |
Anson Funds Management
Dallas,
Texas
|
-$589K |
| 4 |
DAFNA Capital Management
Los Angeles,
California
|
-$192K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$34K |
ATNM Hedge Fund Activity: Q4 2017 in Review
28 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2017, worth a combined $6.39M — down 22% from $8.16M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ATNM and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $230K. The largest seller was Sabby Management, exiting entirely with an estimated $1.4M sold.
- 28 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2017, down from 31 in Q3 2017.
- Funds reported $6.39M of Actinium Pharmaceuticals stock for Q4 2017, down 22% quarter-over-quarter.
- 3 funds opened new Actinium Pharmaceuticals positions in Q4 2017 and 6 closed out, a net change of -3 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2017 was Vanguard Group, an estimated $230K added.
- The largest Actinium Pharmaceuticals seller in Q4 2017 was Sabby Management, an estimated $1.4M sold.
Based on aggregated 13F filings for Q4 2017.